Expert perspectives in ulcerative colitis: An interview with Dr Peter Irving
Ulcerative colitis (UC) is a debilitating inflammatory bowel disease (IBD) affecting approximately 1 in 250 people in the UK.1 Galapagos UK Medical Advisor, Claire Hamilton spoke with Dr Peter Irving on the main issues affecting patients with UC in the UK.
“It’s undoubtedly true that the interaction with pharma companies can be beneficial for patients, not just in the
provision of new treatments, which of course is an essential part of care of UC, but the collaborations
between researchers and industry. They allow us to explore how drugs can be used better in
individuals, but also how we can establish better pathways of treatment”
What should we expect to see when patients present with UC?
UC causes a variety of symptoms, but mainly rectal bleeding, diarrhoea and urgency. I think urgency is probably, in some ways, the worst of those symptoms because it can result in incontinence and that’s a very, very disabling symptom. The time of presentation is often a very stressful time. People may have had symptoms for a long time, even years before getting a diagnosis. Depending on what age they are, people might think they’ve got bowel cancer and, in fact, the diagnosis of UC can almost come as a bit of a relief in some ways.
How does living with UC affect patient quality of life?
Well, that depends how well we treat it or are able to treat it. If you look at the rates of depression and anxiety in people with IBD, then they’re higher than in the general population for understandable reasons. If you think about the effects on daily living, on people’s ability to attend school, on people’s attendance at work when they have UC, on their ability to go out, see their friends and visit restaurants, UC has a sometimes devastating effect on people’s quality of life.
I think sometimes patients hope that we can cure UC, and we can’t. But, like many other medical conditions, we can manage it. I think what many of them do want is treatment that controls their disease to the point that they are able to have good quality of life and where the risks of the medication they’re taking are balanced appropriately with the medication’s effectiveness.
In your opinion, what are the biggest challenges facing the patients in the UK?
I think right now it’s probably dealing with COVID. Some patients have to come to hospital to have their medications as infusions, and those infusion services were potentially disrupted. Patients were also worried about coming to hospital, and were told to stay at home, and possibly even being told to shield. There’s obviously huge uncertainty and anxiety in people with chronic disease and I think many have found the COVID pandemic particularly challenging.
If we put COVID to one side, living with the uncertainty of having a flare up can be challenging and if you do have active disease then there is a significant impact on your life, on your relationships and on your work. Unfortunately, there is a group of people for whom the medication that we use is not effective and their disease is poorly controlled. For these patients, surgery can be required.
What are your biggest concerns about treating patients?
My concerns are based around the fact that we have a growing population of patients with inflammatory bowel disease. People are living longer and so we have a compounding prevalence. So there are challenges in relation to the healthcare system and our ability to cope with all these patients. Then there are challenges posed by the drugs that are available to us because we don’t have the perfect drug yet and there are some patients where, despite an increasing number of treatment options, we still can’t get on top of their disease.
What do you think of the information on UC that’s available to patients?
The abundance of information that is available on the internet can be a problem. The majority of it is completely unregulated and I think it can be tough for patients, particularly if they have a new diagnosis, to be bombarded with information. Some of it is of poor quality, some of it is fantasy, but a lot of it’s very good. I think it’s tough for people to be able to know what’s what.
How can doctors help patients to talk more openly about their condition and get the right information?
Try to find time to listen. I think one has to accept that time is a very limited resource in the NHS and so that is a challenge. Often you will be thinking about that time pressure when you’re seeing a patient knowing how many patients are waiting or how many more patients you have to see, and yet one has to do one’s best to give the patient time.
That brings me on quite nicely to the final question, as a partnership, how can we continue to work to improve the lives of patients with UC?
It’s undoubtedly true that the interaction with pharma companies can be beneficial for patients, not just in the provision of new treatments, which of course is an essential part of care of UC, but the collaborations between researchers and industry. They allow us to explore how drugs can be used better in individuals, but also how we can establish better pathways of treatment. Treating to target is something that’s been talked about a lot over recent years, and some of the trials that have been done in that area have been funded by pharma companies and, to be honest, they wouldn’t be done otherwise. I think it’s really important for us to continue to work in a symbiotic way to improve care for patients with UC over the years.
Thank you, Peter. That was excellent, I really appreciate your time.
- There are unmet need for patients: both newly diagnosed and those living with UC
- It is important that we make good quality information easily accessible to them
- Regaining their pre-diagnosis quality of life is a key goal for patients
There is a pivotal role for the pharmaceutical industry to play as a partner to physicians and their patients, to develop new treatments that can bring hope to people currently suffering from the symptoms of UC. Galapagos specialises in the discovery and development of small molecule medicines with novel modes of action, and supporting clinical research and development. In the UK we are committed to playing an active role within the UK IBD community and collaborating closely with physicians as they work to support their patients at every step in their UC journey.
1. Pasvol TJ, et al. BMJ Open. 2020;10:e036584. doi:10.1136/ bmjopen-2019-036584.